-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HTbvgw1J79nbtJYw5u/bizH4t74b+iGBJJxu9fp2X8ibgVr/M1dFs37fM3xPgEj9 0ZKFRRU+E5RzH49gZ2V9qw== 0000930413-09-000209.txt : 20090109 0000930413-09-000209.hdr.sgml : 20090109 20090109172113 ACCESSION NUMBER: 0000930413-09-000209 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090109 DATE AS OF CHANGE: 20090109 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GREAT POINT PARTNERS LLC CENTRAL INDEX KEY: 0001281446 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A MAIL ADDRESS: STREET 1: 2 PICKWICK PLAZA STREET 2: STE 450 CITY: GREENWICH STATE: CT ZIP: 06830 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEMORY PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001062216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043363475 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-80464 FILM NUMBER: 09519708 BUSINESS ADDRESS: STREET 1: 100 PHILIPS PARKWAY CITY: MONTVALE STATE: NJ ZIP: 07645 BUSINESS PHONE: 2018027100 MAIL ADDRESS: STREET 1: 100 PHILIPS PARKWAY CITY: MONTVALE STATE: NJ ZIP: 07645 SC 13D/A 1 c56299_sc13da.txt ---------------------------- OMB APPROVAL OMB NUMBER: 3235-0145 EXPIRES: FEBRUARY 28, 2009 ESTIMATED AVERAGE BURDEN HOURS PER RESPONSE 14.5 ---------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 6)* MEMORY PHARMACEUTICALS CORP. - -------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $.001 PER SHARE - -------------------------------------------------------------------------------- (Title of Class of Securities) 58606R403 - -------------------------------------------------------------------------------- (CUSIP Number) DAVID GERBER GREAT POINT PARTNERS, LLC 165 MASON STREET, 3RD FLOOR GREENWICH, CT 06830. (203) 971-3300 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) DECEMBER 5, 2008 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] NOTE: Schedule filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER. - -------------------- CUSIP No. 58606R403 - -------------------- =========== =========================================================================================== 1 Names of Reporting Persons. Great Point Partners, LLC I.R.S. Identification Nos. of above persons (entities only). 37-1475292 - ----------- ------------------------------------------------------------------------------------------- 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ] - ----------- ------------------------------------------------------------------------------------------- 3 SEC Use Only - ----------- ------------------------------------------------------------------------------------------- 4 Source of Funds (See Instructions) AF - ----------- ------------------------------------------------------------------------------------------- 5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - ----------- ------------------------------------------------------------------------------------------- 6 Citizenship or Place of Organization Delaware - ----------- ------------------------------------------------------------------------------------------- 7 Sole Voting Power -0- Number of Shares -------- ------------------------------------------------------- 8 Shared Voting Power -0- Beneficially Owned by -------- ------------------------------------------------------- 9 Sole Dispositive Power -0- Each Reporting Person With -------- ------------------------------------------------------- 10 Shared Dispositive Power -0- - -------------------------------------- -------- ------------------------------------------------------- 11 Aggregate Amount Beneficially Owned by Each Reporting Person -0- - ----------- ------------------------------------------------------------------------------------------- 12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] - ----------- ------------------------------------------------------------------------------------------- 13 Percent of Class Represented by Amount in Row (11) 0% - ----------- ------------------------------------------------------------------------------------------- 14 Type of Reporting Person (See Instructions) OO ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- =========== ===========================================================================================
2 - -------------------- CUSIP No. 58606R403 - -------------------- =========== =========================================================================================== 1 Names of Reporting Persons. Dr. Jeffrey R. Jay, M.D. I.R.S. Identification Nos. of above persons (entities only). - ----------- ------------------------------------------------------------------------------------------- 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ] - ----------- ------------------------------------------------------------------------------------------- 3 SEC Use Only - ----------- ------------------------------------------------------------------------------------------- 4 Source of Funds (See Instructions) AF - ----------- ------------------------------------------------------------------------------------------- 5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - ----------- ------------------------------------------------------------------------------------------- 6 Citizenship or Place of Organization United States - ----------- ------------------------------------------------------------------------------------------- 7 Sole Voting Power -0- Number of Shares -------- ------------------------------------------------------- 8 Shared Voting Power -0- Beneficially Owned by -------- ------------------------------------------------------- 9 Sole Dispositive Power -0- Each Reporting Person With -------- ------------------------------------------------------- 10 Shared Dispositive Power -0- - -------------------------------------- -------- ------------------------------------------------------- 11 Aggregate Amount Beneficially Owned by Each Reporting Person -0- - ----------- ------------------------------------------------------------------------------------------- 12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] - ----------- ------------------------------------------------------------------------------------------- 13 Percent of Class Represented by Amount in Row (11) 0% - ----------- ------------------------------------------------------------------------------------------- 14 Type of Reporting Person (See Instructions) IN ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- =========== ===========================================================================================
3 - -------------------- CUSIP No. 58606R403 - -------------------- =========== =========================================================================================== 1 Names of Reporting Persons. Mr. David Kroin I.R.S. Identification Nos. of above persons (entities only). - ----------- ------------------------------------------------------------------------------------------- 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ] - ----------- ------------------------------------------------------------------------------------------- 3 SEC Use Only - ----------- ------------------------------------------------------------------------------------------- 4 Source of Funds (See Instructions) AF - ----------- ------------------------------------------------------------------------------------------- 5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - ----------- ------------------------------------------------------------------------------------------- 6 Citizenship or Place of Organization United States - ----------- ------------------------------------------------------------------------------------------- 7 Sole Voting Power -0- Number of Shares -------- ------------------------------------------------------- 8 Shared Voting Power -0- Beneficially Owned by -------- ------------------------------------------------------- 9 Sole Dispositive Power -0- Each Reporting Person With -------- ------------------------------------------------------- 10 Shared Dispositive Power -0- - -------------------------------------- -------- ------------------------------------------------------- 11 Aggregate Amount Beneficially Owned by Each Reporting Person -0- - ----------- ------------------------------------------------------------------------------------------- 12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] - ----------- ------------------------------------------------------------------------------------------- 13 Percent of Class Represented by Amount in Row (11) 0% - ----------- ------------------------------------------------------------------------------------------- 14 Type of Reporting Person (See Instructions) IN ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- =========== ===========================================================================================
4 - -------------------- CUSIP No. 58606R403 - -------------------- =========== =========================================================================================== 1 Names of Reporting Persons. Biomedical Value Fund, L.P. I.R.S. Identification Nos. of above persons (entities only). 37-1475295 - ----------- ------------------------------------------------------------------------------------------- 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ] - ----------- ------------------------------------------------------------------------------------------- 3 SEC Use Only - ----------- ------------------------------------------------------------------------------------------- 4 Source of Funds (See Instructions) PF - ----------- ------------------------------------------------------------------------------------------- 5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - ----------- ------------------------------------------------------------------------------------------- 6 Citizenship or Place of Organization Delaware - ----------- ------------------------------------------------------------------------------------------- 7 Sole Voting Power -0- Number of Shares -------- ------------------------------------------------------- 8 Shared Voting Power -0- Beneficially Owned by -------- ------------------------------------------------------- 9 Sole Dispositive Power -0- Each Reporting Person With -------- ------------------------------------------------------- 10 Shared Dispositive Power -0- - -------------------------------------- -------- ------------------------------------------------------- 11 Aggregate Amount Beneficially Owned by Each Reporting Person -0- - ----------- ------------------------------------------------------------------------------------------- 12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] - ----------- ------------------------------------------------------------------------------------------- 13 Percent of Class Represented by Amount in Row (11) 0% - ----------- ------------------------------------------------------------------------------------------- 14 Type of Reporting Person (See Instructions) PN ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- =========== ===========================================================================================
5 - -------------------- CUSIP No. 58606R403 - -------------------- =========== =========================================================================================== 1 Names of Reporting Persons. Biomedical Offshore Value Fund, Ltd. I.R.S. Identification Nos. of above persons (entities only). 20-0308288 - ----------- ------------------------------------------------------------------------------------------- 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ] - ----------- ------------------------------------------------------------------------------------------- 3 SEC Use Only - ----------- ------------------------------------------------------------------------------------------- 4 Source of Funds (See Instructions) PF - ----------- ------------------------------------------------------------------------------------------- 5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] - ----------- ------------------------------------------------------------------------------------------- 6 Citizenship or Place of Organization Cayman Islands - ----------- ------------------------------------------------------------------------------------------- 7 Sole Voting Power -0- Number of Shares -------- ------------------------------------------------------- 8 Shared Voting Power -0- Beneficially Owned by -------- ------------------------------------------------------- 9 Sole Dispositive Power -0- Each Reporting Person With -------- ------------------------------------------------------- 10 Shared Dispositive Power -0- - -------------------------------------- -------- ------------------------------------------------------- 11 Aggregate Amount Beneficially Owned by Each Reporting Person -0- - ----------- ------------------------------------------------------------------------------------------- 12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] - ----------- ------------------------------------------------------------------------------------------- 13 Percent of Class Represented by Amount in Row (11) 0% - ----------- ------------------------------------------------------------------------------------------- 14 Type of Reporting Person (See Instructions) OO ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- =========== ===========================================================================================
6 This Amendment No. 6 to Schedule 13D (this "Amendment") is filed by the undersigned to amend the Statement on Schedule 13D, filed by the undersigned on October 24, 2006, as amended by Amendment No. 1, filed by the undersigned on October 17, 2007, as amended by Amendment No. 2, filed by the undersigned on October 17, 2007, as amended by Amendment No. 3, filed by the undersigned on October 22, 2007, as amended by Amendment No. 4, filed on October 24, 2007, as amended by Amendment No. 5, filed on November 6, 2007 (collectively, the "Original Filing"). Unless otherwise indicated, all capitalized terms shall have the same meaning as provided in the Original Filing. Any reference to "this Schedule 13D" in the Original Filing or in this Amendment shall refer to the Original Filing as amended by this Amendment. ITEM 4. PURPOSE OF THE TRANSACTION On December 5, 2008 and December 8, 2008, BMVF sold 527,702 and 22,797 shares, respectively, of Common Stock of the issuer held by it, all for a purchase price of $0.59 per share. On December 5, 2008 and December 8, 2008, BOVF sold 449,523 and 19,418 shares, respectively, of Common Stock of the issuer held by it, all for a purchase price of $0.59 per share. On January 5, 2009, the issuer completed a merger (the "Merger") with 900 North Point Acquisition Corporation, a Delaware corporation ("Merger Sub") and a wholly-owned subsidiary of Hoffmann-La Roche Inc., a New Jersey corporation ("Roche"), pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of November 25, 2008, among the issuer, Roche and Merger Sub (the "Merger Agreement"). Pursuant to the Merger Agreement, all of the common stock of the issuer held by BMVF and BOVF was tendered to Merger Sub at a purchase price of $0.61 per share. As a result of the transactions contemplated by the Merger Agreement, the Reporting Persons no longer beneficially own any securities of the issuer. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER Item 5 is hereby amended and restated as follows: (a) through (b) The Reporting Persons no longer beneficially own any securities of the issuer. (c) See Item 4. (d) Not applicable. (e) January 5, 2009. 7 ITEM 7. MATERIALS TO BE FILED AS EXHIBITS EXHIBIT A: Joint Filing Agreement, dated as of January 9, 2009. 8 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: January 9, 2009 Biomedical Value Fund, L.P. By: Great Point GP, LLC, its general partner By: /s/ Dr. Jeffrey R. Jay -------------------------------- Name: Dr. Jeffrey R. Jay Title: Senior Managing Member Biomedical Offshore Value Fund, Ltd. By: Great Point GP, LLC, its investment manager By: /s/ Dr. Jeffrey R. Jay -------------------------------- Name: Dr. Jeffrey R. Jay Title: Senior Managing Member Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay -------------------------------- Name: Dr. Jeffrey R. Jay Title: Senior Managing Member /s/ Dr. Jeffrey R. Jay ----------------------------------- Dr. Jeffrey R. Jay, individually /s/ Mr. David Kroin ----------------------------------- Mr. David Kroin, individually AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D/A The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D/A to which this Exhibit is attached, and such Schedule 13D/A is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Date: January 9, 2009 Biomedical Value Fund, L.P. By: Great Point GP, LLC, its general partner By: /s/ Dr. Jeffrey R. Jay -------------------------------- Name: Dr. Jeffrey R. Jay Title: Senior Managing Member Biomedical Offshore Value Fund, Ltd. By: Great Point GP, LLC, its investment manager By: /s/ Dr. Jeffrey R. Jay -------------------------------- Name: Dr. Jeffrey R. Jay Title: Senior Managing Member Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay -------------------------------- Name: Dr. Jeffrey R. Jay Title: Senior Managing Member /s/ Dr. Jeffrey R. Jay ----------------------------------- Dr. Jeffrey R. Jay, individually /s/ Mr. David Kroin ----------------------------------- Mr. David Kroin, individually -----END PRIVACY-ENHANCED MESSAGE-----